1H-Pyrazolo[3,4-c]pyridine-3-carboxylic acid, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-, ethyl ester

Endpoint summary

Description of key information

The acute oral lethal dose (LD50) to rats of BMS 589154 -01 was demonstrated to be greater than 2,000 mg/kg bodyweight. Similarly, in an acute dermal toxicity study with BMS-589154-01 in rats, performed according to OECD/EC test guidelines, an LD50 >2000 mg/kg bw was determined.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

September 9 to 30, 2002

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Study was conducted according to OECD and in accordance with GLP. The study material is well characterize

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Qualifier:

according to guideline

Guideline:

EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)

GLP compliance:

yes

Remarks:

ENV/MC/CHEM(98)17 and 1999/11/EC

Test type:

acute toxic class method

Species:

rat

Strain:

other: Hsd:Sprague-Dawley(CD)

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Harlan UK Ltd, Bicester, Oxon, England
- Age at study initiation: 5 - 7 weeks
- Weight at study initiation: 103 to 136 g
- Fasting period before study: overnight prior to, and 4 hours after, dosing.
- Housing: 3 of the same sex in metal cages with wire mesh mesh floors
- Diet: Standard lab rodent diet, ad libitum
- Water: tap water, ad libitum
- Acclimation period: minimum of 7 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±3°C
- Humidity: 40-70 %
- Photoperiod (hrs dark / hrs light):12 hrs artificial light (06:00 - 18:00 hours in each 24hr period.

Route of administration:

oral: gavage

Vehicle:

other: 1% methyl cellulose solution

Details on oral exposure:

by oral gavage using a plastic syringe and catheter (8 ch).

Doses:

dose level: 2,000 mg/kg

No. of animals per sex per dose:

3 females plus 3 males per dose

Control animals:

no

Details on study design:

The cages of the rats were checked at least twice daily for any mortalities.
Animals were observed soon after dosing and at frequent intervals for the remainder of day 1. On subsequent days animals were observed once in the morning and at the end of each experimental day (with the exception of day 15 - morning only).
All animals were observed for 14 days after dosing.

Sex:

male

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Sex:

female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

There were no deaths following a single oral gavage dose to a group of 6 rats (3 male/3 female) at a dose level of 2,000mg/kg bodyweight.

Clinical signs:

other: 1 female, on day 1, showed signs of piloerection. Recovery was complete by day 2.

Interpretation of results:

GHS criteria not met

Conclusions:

The acute oral median lethal dose (LD50) of the test material was greater than 2000 mg/kg bodyweight

Executive summary:

The acute oral lethal dose (LD50) to rats of BMS 589154 -01 was demonstrated ot be greater than 2,000 mg/kg bodyweight.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating dose

Value:

2 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Link to relevant study records

Reference

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Study period:

14 June 2016 - 29 June 2016

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Version / remarks:

1987

Deviations:

no

Qualifier:

according to guideline

Guideline:

EU Method B.3 (Acute Toxicity (Dermal))

Version / remarks:

May 2008, including most recent amendments

Deviations:

no

Qualifier:

according to guideline

Guideline:

EPA OPPTS 870.1200 (Acute Dermal Toxicity)

Version / remarks:

August 1998

Deviations:

no

Qualifier:

according to guideline

Guideline:

other: Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF), 12 Nousan, Notification No 8147.

Version / remarks:

November 2000; including the most recent partial revisions.

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Remarks:

; date certificate 03 November 2015

Test type:

standard acute method

Limit test:

yes

Specific details on test material used for the study:

Test item handling: Use amber glassware or wrap container in aluminum-foil
pH (1% in water, indicative range): 4.5 – 4.4 (determined by Charles River Den Bosch)
Stability in vehicle (Propylene glycol): Stability for at least 5 hours at room temperature is confirmed over the concentration range 1 to 200 mg/mL

Species:

rat

Strain:

other: Wistar strain, Crl:WI (Han)

Sex:

male/female

Details on test animals or test system and environmental conditions:

- Source: Charles River Deutschland, Sulzfeld, Germany.
- Age at study initiation: Young adult animals (approx. 12 weeks old)
- Weight at study initiation: males 329 - 341 grams, females 194 - 219 grams.
- Housing: Individually housed in labeled Makrolon cages containing sterilized sawdust as bedding material and paper as cage-enrichment.
- Diet: Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany).
- Water: Free access to tap water.
- Acclimation period: At least 5 days

ENVIRONMENTAL CONDITIONS (set to maintain)
- Temperature (°C): 18 – 24
- Humidity (%): 40 - 70
- Air changes (per hr): approx 10
- Photoperiod (hrs dark / hrs light): 12/12

Deviations from the maximum level of daily mean relative humidity occurred. Evaluation: Laboratory historical data do not indicate an effect of the deviations. The study integrity was not adversely affected by the deviation.

IN-LIFE DATES: From: 14 June 2016 to 29 June 2016

Type of coverage:

occlusive

Vehicle:

propylene glycol

Remarks:

The vehicle was selected based on trial preparation performed at Charles River Den Bosch and on test item data supplied by the Sponsor.

Details on dermal exposure:

One day before exposure (Day -1) an area of approximately 5x7 cm on the back of the animal was clipped.

TEST ITEM PREPARATION
The preparation (w/w) was kept at room temperature protected from light and dosed within 4 hours after adding the vehicle to the test item. Homogeneity was assessed by visual inspection of the solutions and the formulations were stirred during dosing, which ensures homogeneity sufficient for these kinds of studies. Adjustment was made for specific gravity of the vehicle. No correction was made for purity of the test item.

TREATMENT
Method: Dermal application. The test item (preparation) was stirred on a magnetic stirrer during application.
Clipping: One day before exposure (Day -1) an area of approximately 5x7 cm on the back of each animal was clipped.
Application: The test item preparation was applied on an area of approx. 10% of the total body surface, i.e. approx. 25 cm² for males and 18 cm² for females. The test item preparation was held in contact with the skin with a dressing, consisting of a surgical gauze patch (Surgy 1D), successively covered with aluminum foil and Coban elastic bandage. A piece of Micropore tape was additionally used for fixation of the bandages in females only.
Frequency: Single dosage, on Day 1.
Washing: Following 24 hour exposure, dressings were removed and the skin cleaned of residual test substance using tap water.

Duration of exposure:

24 hours.

Doses:

2000 mg/kg (10 mL/kg) body weight

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Mortality/Viability: Twice daily
Body weights: Days 1 (pre-administration), 8 and 15.
Clinical signs: At periodic intervals on the day of dosing (Day 1) and once daily thereafter, until Day 15.
Necropsy: At the end of the observation period, all animals were euthanatized by oxygen/carbon dioxide procedure and subjected to necropsy. Descriptions of all internal macroscopic abnormalities were recorded.

Statistics:

None.

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

No mortality occurred.

Clinical signs:

other: Restless behaviour, piloerection, ptosis and/or chromodacryorrhoea (snout) were noted for several animals on Day 1. Maculate erythema, general erythema, scales and/or scabs were noted for several animals between Days 8 and 15. These local effects were con

Gross pathology:

No abnormalities were found at macroscopic post mortem examination of the animals.

Interpretation of results:

GHS criteria not met

Conclusions:

In an acute dermal toxicity study with BMS-589154-01 in rats, performed according to OECD/EC test guidelines, an LD50 >2000 mg/kg bw was determined.

Executive summary:

Assessment of acute dermal toxicity with BMS-589154-01 in the rat was performed according to OECD/EC guidelines and in compliance with GLP principles. BMS-589154-01 was administered to five Wistar rats of each sex by a single dermal application at 2000 mg/kg bw for 24 hours. Animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed after terminal euthanasia (Day 15). No mortality occurred. Restless behaviour, piloerection, ptosis and/or chromodacryorrhoea (snout) were noted for several animals on Day 1. Maculate erythema, general erythema, scales and/or scabs were noted for several animals between Days 8 and 15. These local effects were considered not to have affected the conclusion of the study. The mean body weight gain during the observation period was within the range expected for rats used in this type of study. No abnormalities were found at macroscopic post mortem examination of the animals.

The dermal LD50 value of BMS-589154-01 in Wistar rats was established to exceed 2000 mg/kg bw.

Based on these results, BMS-589154-01 does not have to be classified and has no obligatory labelling requirement for acute dermal toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2015) (including all amendments) and Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments).

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating dose

Value:

2 000 mg/kg bw

Justification for classification or non-classification

The acute oral lethal dose (LD50) to rats of BMS 589154 -01 was demonstrated to be greater than 2,000 mg/kg bodyweight. Similarly, in an acute dermal toxicity study with BMS-589154-01 in rats, performed according to OECD/EC test guidelines, an LD50 >2000 mg/kg bw was determined.

Therefore the substance does not meet the criteria for classification as acutely toxic as set out in 1272/2008/EC (amended).